We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Henk
Giele
-
henk.giele@mac.com
Ms
Aimee
Henessy
-
ssftrial@nds.ox.ac.uk
Dr
Jessica
Scaife
-
jessica.scaife@nds.ox.ac.uk
Organ rejection
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Transplanted organs such as lungs, hearts, kidneys and pancreases are subject to attack by the immune system causing rejection of the transplanted organ. Rejection is prevented by immunosuppression medication that interferes with the body’s immune system and hinders rejection. Despite these medications rejection still occurs. If rejection is not detected and treated early enough the transplanted organ scars and stops working. Detecting rejection is difficult as it does not have specific features. In lung transplants attempts are made to detect rejection by frequent hospital visits for chest x-rays, blood tests and biopsies of the transplanted lung performed by putting a tube into the airway down into the lung. These tests are performed very regularly or of the patient has symptoms of lung disease such as cough. All these tests can show are if there is inflammation but there is no specific measure of rejection until the rejection is very severe.
We discovered when we were doing intestinal transplants which included skin transplants that the skin displayed a easily visible rash when rejection was occurring, and that this sign was present before the intestine transplant rejected. The skin was visible continuously, so we did not have to rely on intermittent biopsies or other tests, but only performed these when the skin indicated there was rejection. As a result of this we began a trial, transplanting a patch of skin with pancreas and kidney transplants. Our preliminary results show that the skin not only acts as a monitor for rejection but also reduces the risk of rejection in transplants.
We wish to repeat this study in lung transplants to see if a skin transplant can act as a rejection monitor for lung transplants, reduce the immune suppression drug levels, and avoid rejection injury to the lungs.
The aim of the SENTINEL study is to find out whether transplanting both lung and a patch of skin (called a sentinel skin flap) from the same donor helps to reduce rejection of the lung.
The skin will be transplanted onto the under-surface of the lower arm.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Any significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to comply with trial procedures2. Severe peripheral vascular disease with no vessels available for inset of the skin flap
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Jessica
Scaife
-
jessica.scaife@nds.ox.ac.uk
Prof
Henk
Giele
-
henk.giele@mac.com
Ms
Aimee
Henessy
-
ssftrial@nds.ox.ac.uk
The study is sponsored by University of Oxford and funded by NIHR EME.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 55602
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
